Mealey's (August 3, 2021, 3:10 PM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on July 28 told patients and health care professionals that post-approval clinical trial results show an increased risk of death associated with Pepaxto brand melphalan flufenamide, a drug approved in February under an accelerated approval process, to treat patients with multiple myeloma....